Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients
Ákos Nádasdi,György Sinkovits,Ilona Bobek,B. Lakatos,Zsolt Förhécz,Zita Z. Prohászka,Marienn Réti,Miklós Arató,Gellért Cseh,Tamás Masszi,Béla Merkely,Péter Ferdinandy,Istvan Valyi-Nagy,Zoltán Prohászka,Gábor Firneisz +14 more
TLDR
Investigation of serum circulating DPP4 activity in patients with COVID-19 disease found a significant decrease was found in study groups of higher disease severity and is a strong prognostic biomarker of mortality.Abstract:
Aim: To investigate the serum circulating DPP4 activity in patients with COVID-19 disease. Materials & methods: Serum samples from 102 hospitalized COVID-19 patients and 43 post-COVID-19 plasma donors and 39 SARS-CoV-2 naive controls and their medical data were used. Circulating DPP4 activities according to different COVID-19 disease peak severity (WHO) groups at sampling and at peak were assessed. Results: A significant decrease (p < 0.0001) in serum DPP4 activity was found in study groups of higher disease severity. When the circulating DPP4 activity was assessed as a prognostic marker, the logistic regression (p = 0.0023) indicated that the enzyme activity is a predictor of mortality (median 9.5 days before death) with receiver operating characteristic area under the curves of 73.33% (p[area = 0.5] < 0.0001) as single predictor and 83.45% (p[area = 0.5] < 0.0001) in combination with age among hospitalized patients with COVID-19. Conclusion: Decreased circulating DPP4 activity is associated with severe COVID-19 disease and is a strong prognostic biomarker of mortality.read more
Citations
More filters
Journal ArticleDOI
Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
TL;DR: It is shown that the broad spectrum of functions regulated by DPP4 is performed both as a protease enzyme, as well as an interacting partner of other molecules on the cell surface, which indicates that the pathogenetic links between COVID-19 and diabetes mellitus and the hyperinflammatory response are severe.
Journal ArticleDOI
The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS – a critical overview
TL;DR: For a number of diseases, use of DPP4 inhibitors has been shown to have a disease-mitigating effect, however, these beneficial effects should mostly be attributed to the depression of “peripheral” DPP 4, since currently used DPP3 inhibitors are not able to pass through the intact blood–brain barrier.
Journal ArticleDOI
Prognostic models in COVID-19 infection that predict severity: a systematic review
Chepkoech Buttia,Erand Llanaj,Hamidreza Raeisi-Dehkordi,Lum Kastrati,Mojgan Amiri,Renald Mecani,Petek Eylul Taneri,Sergio Alejandro Gómez Ochoa,Peter Francis Raguindin,Faina Wehrli,Farnaz Khatami,O. Espinola,Lyda Z. Rojas,Aurélie Pahud de Mortanges,Eric Francis Macharia-Nimietz,Fadi Alijla,Beatrice Minder,Alexander Benedikt Leichtle,Nora Lüthi,S. Ehrhard,Yok-Ai Que,Laurenz Kopp Fernandes,Wolf E. Hautz,Taulant Muka +23 more
TL;DR: A systematic review of the available studies that have developed, assessed and/or validated prognostic models of COVID-19 predicting health outcomes is presented in this article , with a focus on adverse outcomes.
Journal ArticleDOI
Saxagliptin Cardiotoxicity in Chronic Heart Failure: The Role of DPP4 in the Regulation of Neuropeptide Tone
Imre Vörös,Zsófia Onódi,Viktória E. Tóth,Tamás G Gergely,Éva Sághy,Anikó Görbe,Ágnes Kemény,Przemysław Leszek,Zsuzsanna Helyes,Péter Ferdinandy,Zoltán Varga +10 more
TL;DR: In this article , the authors established a cellular platform to investigate DPP4 inhibition and the role of its neuropeptide substrates substance P (SP) and NPY (NPY).
Journal ArticleDOI
Effect of DPP4/CD26 expression on SARS-CoV-2 susceptibility, immune response, adenosine (derivatives m62A and CD) regulations on patients with cancer and healthy individuals
TL;DR: In this paper , the authors used the Human Protein Atlas, Monaco, and Schmiedel databases to analyze the expression of DPP4 in human tissues and immune cells, and the association between DPP 4 expression and survival in various tumor tissues was compared using GEPIA 2.
References
More filters
Journal ArticleDOI
Clinical Characteristics of Coronavirus Disease 2019 in China.
Wei-jie Guan,Zhengyi Ni,Yu Hu,Wenhua Liang,Chun-Quan Ou,Jianxing He,Lei Liu,Hong Shan,Chunliang Lei,David S.C. Hui,Bin Du,Lanjuan Li,Guang Zeng,Kowk-Yung Yuen,Ruchong Chen,Chun-Li Tang,Tao Wang,Ping-Yan Chen,Jie Xiang,Shiyue Li,Jinlin Wang,Zi-jing Liang,Yi-xiang Peng,Li Wei,Yong Liu,Ya-hua Hu,Peng Peng,Jian-ming Wang,Ji-yang Liu,Zhong Chen,Gang Li,Zhi-jian Zheng,Shao-qin Qiu,Jie Luo,Chang-jiang Ye,Shao-yong Zhu,Nanshan Zhong +36 more
TL;DR: During the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness, and patients often presented without fever, and many did not have abnormal radiologic findings.
Journal ArticleDOI
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Fei Zhou,Ting Yu,Ronghui Du,Guohui Fan,Ying Liu,Zhibo Liu,Jie Xiang,Yeming Wang,Bin Song,Xiaoying Gu,Xiaoying Gu,Lulu Guan,Yuan Wei,Li Hui,Xudong Wu,Jiuyang Xu,Shengjin Tu,Yi Zhang,Hua Chen,Bin Cao +19 more
TL;DR: Wang et al. as discussed by the authors used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death, including older age, high SOFA score and d-dimer greater than 1 μg/mL.
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou,Ting Yu,Ronghui Du,Guohui Fan,Ying Liu,Zhibo Liu,Jie Xiang,Yeming Wang,Bin Song,Xiaoying Gu,Xiaoying Gu,Lulu Guan,Yuan Wei,Li Hui,Xudong Wu,Jiuyang Xu,Shengjin Tu,Yi Zhang,Hua Chen,Bin Cao +19 more
TL;DR: Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.
Journal ArticleDOI
SARS and MERS: recent insights into emerging coronaviruses
TL;DR: The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 marked the second introduction of a highly pathogenic coronav virus into the human population in the twenty-first century, and the current state of development of measures to combat emerging coronaviruses is discussed.
Journal ArticleDOI
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
V. Stalin Raj,Huihui Mou,Saskia L. Smits,Dick H. W. Dekkers,Marcel A. Müller,Ronald Dijkman,Doreen Muth,Jeroen Demmers,Ali Moh Zaki,Ron A. M. Fouchier,Volker Thiel,Volker Thiel,Christian Drosten,Peter J. M. Rottier,Albert D. M. E. Osterhaus,Berend Jan Bosch,Bart L. Haagmans +16 more
TL;DR: Dipeptidyl peptidase 4 (DPP4; also known as CD26) is identified as a functional receptor for hCoV-EMC and will contribute critically to the understanding of the pathogenesis and epidemiology of this emerging human coronavirus, and may facilitate the development of intervention strategies.